Filing Analysis
Neumora Therapeutics announced a leadership transition effective August 14, 2026, where President Joshua Pinto, Ph.D., succeeds Paul L. Berns as CEO, while Berns moves to Executive Chairperson.
🚩 Red Flags
- Sudden CEO transition (effective immediately upon filing/report date) can sometimes indicate internal friction or strategic shifts, though not explicitly stated here.
📋 Key Facts
- Effective Date: August 14, 2026
- New CEO: Joshua Pinto, Ph.D. (formerly President)
- Outgoing CEO/New Role: Paul L. Berns becomes Executive Chairperson of the Board
- Dr. Pinto also appointed as a Class III director with a term expiring at the 2029 Annual Meeting
- The leadership transition was approved by the Board on August 12, 2026
Neumora Therapeutics announced favorable pre-clinical toxicology results for its drug candidate NMRA-215 via a press release on July 27, 2026.
📋 Key Facts
- Announced favorable pre-clinical toxicology results for NMRA-215.
- The announcement was made via a press release dated July 27, 2026.
- Filing includes Exhibit 99.1 containing the full press release.
Neumora Therapeutics, Inc. announced the conversion of $2.5 million of outstanding term loan principal into common stock. This follows a previous amendment to a Loan and Security Agreement with K2 HealthVentures LLC.
🚩 Red Flags
- Dilution risk: The conversion at a specific price ($0.8774) suggests potential downward pressure on share price if market value is higher.
- Debt-to-Equity Conversion: Frequent use of debt conversion as a mechanism for lender repayment can indicate liquidity constraints or a preference by lenders to take equity positions over cash repayments.
📋 Key Facts
- K2 HealthVentures LLC (K2HV) exercised its right to convert $2.5 million of principal amount of the term loan into common stock.
- The conversion price was set at $0.8774 per share.
- A total of 2,849,327 shares of common stock were issued on November 20, 2025.
- The issuance was made in reliance on the Section 4(a)(2) registration exemption of the Securities Act of 1933.
- K2HV retains the right to convert up to an aggregate of $12.5 million of outstanding principal.
Neumora Therapeutics, Inc. announced its financial results for the second quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Second quarter ended September 30, 2025
- The company furnished results under Item 2.02 of Form 8-K
- Financial results were released via press release (Exhibit 99.1)
Neumora Therapeutics announced the initiation of a Phase 1 single-ascending dose and multiple-ascending dose (SAD/MAD) study for its candidate NMRA-898. This is a routine clinical development update typical for biotechnology companies.
📋 Key Facts
- Initiation of Phase 1 SAD/MAD study for NMRA-898 announced on October 27, 2025.
- The announcement was made via press release (Exhibit 99.1).
Neumora Therapeutics announced positive preclinical data for its oral NLRP3 inhibitor, NMRA-215, across three diet-induced obesity (DIO) mouse studies. The results showed significant weight loss in both monotherapy and combination therapy with semaglutide.
🚩 Red Flags
- Preclinical data only; results in animal models do not guarantee clinical success in humans.
📋 Key Facts
- NMRA-215 demonstrated up to 19% weight loss as a monotherapy in DIO mouse studies.
- Combination of NMRA-215 and high doses of semaglutide resulted in 26% weight loss.
- The drug is described as a highly brain-penetrant, oral NLRP3 inhibitor.
- Data was derived from three separate diet-induced obesity (DIO) mouse studies.
Neumora Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2025.
- Announcement date: August 6, 2025.
- The filing includes Exhibit 99.1 containing the full text of the press release.
Neumora Therapeutics held its Annual Meeting of Stockholders on May 28, 2025, where shareholders approved several key items including the election of directors and a reverse stock split. Most notably, stockholders approved amendments to allow for a reverse stock split with a ratio between 1-for-5 and 1-for-30.
🚩 Red Flags
- Approval of a reverse stock split (ratio up to 1-for-30) is often used to maintain Nasdaq listing compliance or improve share price perception.
- Repricing of stock options (Proposal 3) can be viewed as dilutive or indicative of poor historical performance relative to option strike prices.
📋 Key Facts
- Annual Meeting held on May 28, 2025.
- Proposal 4: Shareholders approved a reverse stock split ranging from 1-for-5 to 1-for-30, as determined by the Board.
- Proposal 1: Election of Alaa Halawa and Maykin Ho, Ph.D. to Class II directors.
- Proposal 2: Ratification of Ernst & Young LLP as independent auditors for fiscal year ending Dec 31, 2025.
- Proposal 3: Approval of repricing certain outstanding stock options under the 2020 and 2023 Incentive Plans.
- Record date for voting was April 28, 2025; 161,747,922 shares were outstanding/entitled to vote.
Neumora Therapeutics received a notice from Nasdaq stating it is non-compliant with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The company has until November 10, 2025, to regain compliance and is considering a reverse stock split as a potential remedy.
🚩 Red Flags
- Delisting notice from Nasdaq (non-compliance with minimum bid price).
- Proposed reverse stock split (1-for-5 to 1-for-30) to artificially inflate share price.
- Potential for delisting if compliance is not met by November 2025.
📋 Key Facts
- Received notice from Nasdaq on May 14, 2025, regarding non-compliance with Listing Rule 5450(a)(1).
- The company has a 180-day compliance period ending November 10, 2025.
- To regain compliance, the stock must close at or above $1.00 for ten consecutive business days within the window.
- A reverse stock split (ratio between 1-for-5 and 1-for-30) has been proposed and will be voted on by stockholders on May 28, 2025.
- Failure to regain compliance may lead to delisting or a transfer to the Nasdaq Capital Market.
Neumora Therapeutics announced its financial results for the first quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2025.
- Announcement date: May 12, 2025.
- The company furnished results under Item 2.02 of Form 8-K.
- Financial statements and press release are provided in Exhibit 99.1.
Neumora Therapeutics is amending its previous 8-K to disclose a revision in the terms of a stock option repricing plan. The Board has updated the mechanism for determining the new exercise price, moving from the February 13, 2025 closing price to the closing price on the date of the 2025 annual stockholder meeting (scheduled for May 28, 2025).
🚩 Red Flags
- Related-party transaction: The repricing specifically benefits members of the Board and named executive officers.
- Potential dilution/incentive misalignment: Repricing options is often a sign that the company's stock price has fallen significantly below previous strike prices, potentially signaling poor market performance or capital structure distress.
📋 Key Facts
- The Board approved a conditional reduction in exercise prices for certain outstanding stock options held by directors, employees, and named executive officers.
- The repricing is subject to stockholder approval.
- Revised terms: The new exercise price will equal the closing trading price on the date of the 2025 annual stockholder meeting (May 28, 2025), rather than the February 13, 2025 price.
- Eligible options must be exercised on or after August 13, 2026, to qualify for the repriced rate.
Neumora Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2024. The filing serves as a formal announcement of earnings via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2024.
- Announcement date: March 3, 2025.
- The information provided under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Neumora Therapeutics, Inc. announced a major leadership transition involving the departure of President and CEO Henry Gosebruch and the appointment of Paul L. Berns as Chairman and CEO.
🚩 Red Flags
- Sudden departure of the President and CEO (Henry Gosebruch).
- Significant severance/separation package for outgoing CEO including base salary and bonus payments.
📋 Key Facts
- Henry Gosebruch has entered into a Separation Agreement effective February 14, 2025.
- Gosebruch will receive base salary for 12 months, his 2025 target bonus, and 18 months of COBRA coverage.
- Paul L. Berns appointed as Chairman and CEO, superseding his previous role as Executive Chairman.
- Berns' new compensation includes a $700,000 annual base salary and a 60% target bonus.
- Berns was awarded an option to purchase 2,000,000 shares of common stock, vesting over four years.
Neumora Therapeutics announced a major leadership overhaul effective February 14, 2025, including the return of Co-Founder Paul Berns as CEO and the departure of President/CEO Henry Gosebruch. The filing also details significant executive compensation changes and a proposed stock option repricing subject to shareholder approval.
🚩 Red Flags
- Significant leadership turnover (CEO/President departure and replacement).
- Proposed option repricing: This is often viewed as a red flag in micro-cap/biotech sectors as it suggests the stock price has fallen significantly below previous strike prices, necessitating 'rescue' measures to maintain employee incentives.
- Large signing bonuses ($970k for Pinto, $860k for Aurora) subject to clawback provisions.
📋 Key Facts
- Paul L. Berns transitions from Executive Chairman to CEO and Chairman of the Board, effective Feb 14, 2025.
- Henry Gosebruch departs as President, CEO, and Board member.
- Joshua Pinto promoted from CFO to President; granted a $970,000 signing bonus (subject to clawback) and 3,000,000 stock options.
- Bill Aurora promoted to Chief Operating and Development Officer; granted an $860,000 signing bonus (subject to clawback) and 1,000,000 stock options.
- Michael Milligan appointed CFO in addition to his role as principal accounting officer.
- The Board approved a stock option repricing for eligible service providers, contingent on stockholder approval, to lower exercise prices to the Feb 13, 2025 closing price.
Neumora Therapeutics, Inc. filed an 8-K to furnish a corporate presentation intended for use at the 43rd Annual J.P. Morgan Healthcare Conference.
📋 Key Facts
- The filing was made on January 13, 2025.
- The company is providing a corporate presentation (Exhibit 99.1) to be used for meetings with investors and analysts at the J.P. Morgan Healthcare Conference.
- The information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act.
Neumora Therapeutics announced the results of its Phase 3 KOASTAL-1 study for navacaprant in treating major depressive disorder (MDD). The filing serves as a vehicle to incorporate the press release containing clinical trial data into the company's official SEC records.
🚩 Red Flags
- Clinical trial results in biotech are binary; failure to meet primary endpoints would be a critical risk, though specific data is contained in Exhibit 99.1 rather than the 8-K text itself.
📋 Key Facts
- Announcement date: January 2, 2025
- Clinical Study: Phase 3 KOASTAL-1 study
- Drug Candidate: navacaprant
- Indication: Major Depressive Disorder (MDD)
- Exhibit 99.1 contains the full press release with detailed results.
Neumora Therapeutics, Inc. announced its financial results for the third quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 12, 2024
- Reporting period: Third Quarter ended September 30, 2024
- The company is classified as an emerging growth company
- Financial results were furnished via Exhibit 99.1 (Press Release)
Neumora Therapeutics, Inc. announced its financial results for the second quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release issued on August 6, 2024.
📋 Key Facts
- Reporting period: Second Quarter ended June 30, 2024
- Announcement date: August 6, 2024
- The filing includes Exhibit 99.1 containing the full press release of financial results.
- Company is classified as an 'emerging growth company'.
Neumora Therapeutics, Inc. held its Annual Meeting of Stockholders on June 13, 2024. The meeting resulted in the successful election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 13, 2024.
- Proposal 1: Election of Class I directors Henry O. Gosebruch and Kristina Burow was successful.
- Proposal 2: Ratification of Ernst & Young LLP as independent registered public accounting firm for FY2024 was approved with 102,921,992 votes in favor.
- As of the April 15, 2024 record date, 159,452,584 shares were outstanding and entitled to vote.
Neumora Therapeutics, Inc. announced its financial results for the first quarter ended March 31, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: First Quarter ended March 31, 2024.
- Announcement date: May 7, 2024.
- The company is classified as an emerging growth company.
Neumora Therapeutics announced that the FDA has placed a clinical hold on its Phase 1 trial of NMRA-266, a M4 muscarinic receptor modulator. The hold was triggered by preclinical data showing convulsions in rabbits, though no such side effects have been observed in the approximately 30 human participants dosed to date.
🚩 Red Flags
- Clinical hold by the FDA on a lead/key asset (NMRA-266).
- Safety signal in preclinical models (convulsions in rabbits) directly impacting clinical progress.
- Withdrawal of previous company guidance regarding the drug's development timeline or outlook.
📋 Key Facts
- FDA placed a clinical hold on the Phase 1 trial of NMRA-266 (M4 PAM franchise).
- The decision follows preclinical data showing convulsions in rabbits.
- Phase 1 single ascending dose/multiple ascending dose study is currently paused.
- Approximately 30 participants have been dosed with no observed convulsions in humans.
- Prior guidance regarding NMRA-266 is no longer applicable as of April 15, 2024.
Neumora Therapeutics announced its financial results for the fourth quarter and full year ended December 31, 2023. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Fourth quarter and full year ended December 31, 2023.
- Announcement date: March 7, 2024.
- The filing includes Exhibit 99.1 containing the full press release of financial results.
Neumora Therapeutics, Inc. filed an 8-K to furnish a corporate presentation intended for use at the 42nd Annual J.P. Morgan Healthcare Conference. The filing is made pursuant to Item 7.01 (Regulation FD Disclosure) and does not contain material non-public information or financial changes.
📋 Key Facts
- The company furnished a corporate presentation dated January 2024 as Exhibit 99.1.
- The presentation is intended for meetings with investors and analysts at the 42nd Annual J.P. Morgan Healthcare Conference.
- The information provided under Item 7.01 is not considered 'filed' for purposes of Section 18 of the Exchange Act or subject to liability under Sections 11 and 12(a)(2) of the Securities Act.